The addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma

Simon Johannes Gairing, Felix Thol, Lukas Müller, Felix Hahn, Thomas Thomaidis, Carolin Czauderna, Fabian Bartsch, Michael Bernhard Pitton, Jens Uwe Marquardt, Marcus Alexander Wörns, Peter Robert Galle, Markus Moehler, Arndt Weinmann, Roman Kloeckner, Friedrich Foerster*

*Korrespondierende/r Autor/-in für diese Arbeit
2 Zitate (Scopus)


Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months in the pCTX + TACE group versus 13.1 months in the pCTX group (p = 0.008). Controlling for albumin, bilirubin, ECOG (Eastern Cooperative Oncology Group) performance status, and UICC (Union for International Cancer Control) stage, the addition of TACE still conferred an OS benefit of 12.95 months (p = 0.014). A propensity score matching analysis yielded an OS benefit of 14 months from the time of unresectability for the pCTX + TACE group (p = 0.020). The addition of TACE to pCTX may provide an OS benefit for patients with unresectable iCCA. Thus, patients with liver-dominant iCCA undergoing standard-of-care pCTX should be considered for additional treatment with TACE.

ZeitschriftJournal of Clinical Medicine
PublikationsstatusVeröffentlicht - 02.06.2021


Untersuchen Sie die Forschungsthemen von „The addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma“. Zusammen bilden sie einen einzigartigen Fingerprint.